672 related articles for article (PubMed ID: 16036307)
1. Water-soluble polymers for targeted drug delivery to human squamous carcinoma of head and neck.
Nan A; Ghandehari H; Hebert C; Siavash H; Nikitakis N; Reynolds M; Sauk JJ
J Drug Target; 2005 Apr; 13(3):189-97. PubMed ID: 16036307
[TBL] [Abstract][Full Text] [Related]
2. Synthesis and in vitro anti-tumor activity of novel HPMA copolymer-drug conjugates with potential cell surface targeting property for carcinoma cells.
Xiang Q; Yang Y; Zhou Z; Zhou D; Jin Y; Zhang Z; Huang Y
Eur J Pharm Biopharm; 2012 Feb; 80(2):379-86. PubMed ID: 22101181
[TBL] [Abstract][Full Text] [Related]
3. Targeting of human squamous carcinomas by SPA470-doxorubicin immunoconjugates.
Hebert C; Norris K; Sauk JJ
J Drug Target; 2003 Feb; 11(2):101-7. PubMed ID: 12881196
[TBL] [Abstract][Full Text] [Related]
4. Targeted delivery of doxorubicin by HPMA copolymer-hyaluronan bioconjugates.
Luo Y; Bernshaw NJ; Lu ZR; Kopecek J; Prestwich GD
Pharm Res; 2002 Apr; 19(4):396-402. PubMed ID: 12033370
[TBL] [Abstract][Full Text] [Related]
5. HPMA copolymer-anticancer drug-OV-TL16 antibody conjugates. II. Processing in epithelial ovarian carcinoma cells in vitro.
Omelyanenko V; Gentry C; Kopecková P; Kopecek J
Int J Cancer; 1998 Feb; 75(4):600-8. PubMed ID: 9466663
[TBL] [Abstract][Full Text] [Related]
6. Targetable HPMA copolymer-adriamycin conjugates. Recognition, internalization, and subcellular fate.
Omelyanenko V; Kopecková P; Gentry C; Kopecek J
J Control Release; 1998 Apr; 53(1-3):25-37. PubMed ID: 9741911
[TBL] [Abstract][Full Text] [Related]
7. Design of a multivalent galactoside ligand for selective targeting of HPMA copolymer-doxorubicin conjugates to human colon cancer cells.
David A; Kopecková P; Minko T; Rubinstein A; Kopecek J
Eur J Cancer; 2004 Jan; 40(1):148-57. PubMed ID: 14687799
[TBL] [Abstract][Full Text] [Related]
8. Overcoming multidrug resistance in Dox-resistant neuroblastoma cell lines via treatment with HPMA copolymer conjugates containing anthracyclines and P-gp inhibitors.
Koziolová E; Janoušková O; Cuchalová L; Hvězdová Z; Hraběta J; Eckschlager T; Sivák L; Ulbrich K; Etrych T; Šubr V
J Control Release; 2016 Jul; 233():136-46. PubMed ID: 27189135
[TBL] [Abstract][Full Text] [Related]
9. Assessing the therapeutic efficacy of VEGFR-1-targeted polymer drug conjugates in mouse tumor models.
Shamay Y; Golan M; Tyomkin D; David A
J Control Release; 2016 May; 229():192-199. PubMed ID: 27001892
[TBL] [Abstract][Full Text] [Related]
10. Properties of HPMA copolymer-doxorubicin conjugates with pH-controlled activation: effect of polymer chain modification.
Chytil P; Etrych T; Konák C; Sírová M; Mrkvan T; Ríhová B; Ulbrich K
J Control Release; 2006 Sep; 115(1):26-36. PubMed ID: 16899320
[TBL] [Abstract][Full Text] [Related]
11. Pronounced Cellular Uptake of Pirarubicin versus That of Other Anthracyclines: Comparison of HPMA Copolymer Conjugates of Pirarubicin and Doxorubicin.
Nakamura H; Koziolová E; Chytil P; Tsukigawa K; Fang J; Haratake M; Ulbrich K; Etrych T; Maeda H
Mol Pharm; 2016 Dec; 13(12):4106-4115. PubMed ID: 27934482
[TBL] [Abstract][Full Text] [Related]
12. Investigating the mechanism of enhanced cytotoxicity of HPMA copolymer-Dox-AGM in breast cancer cells.
Greco F; Vicent MJ; Gee S; Jones AT; Gee J; Nicholson RI; Duncan R
J Control Release; 2007 Jan; 117(1):28-39. PubMed ID: 17129632
[TBL] [Abstract][Full Text] [Related]
13. Intratumoral Distribution and pH-Dependent Drug Release of High Molecular Weight HPMA Copolymer Drug Conjugates Strongly Depend on Specific Tumor Substructure and Microenvironment.
Noack AK; Lucas H; Chytil P; Etrych T; Mäder K; Mueller T
Int J Mol Sci; 2020 Aug; 21(17):. PubMed ID: 32825790
[TBL] [Abstract][Full Text] [Related]
14. Star structure of antibody-targeted HPMA copolymer-bound doxorubicin: a novel type of polymeric conjugate for targeted drug delivery with potent antitumor effect.
Kovár M; Strohalm J; Etrych T; Ulbrich K; Ríhová B
Bioconjug Chem; 2002; 13(2):206-15. PubMed ID: 11906257
[TBL] [Abstract][Full Text] [Related]
15. A comparative study of folate receptor-targeted doxorubicin delivery systems: dosing regimens and therapeutic index.
Scomparin A; Salmaso S; Eldar-Boock A; Ben-Shushan D; Ferber S; Tiram G; Shmeeda H; Landa-Rouben N; Leor J; Caliceti P; Gabizon A; Satchi-Fainaro R
J Control Release; 2015 Jun; 208():106-20. PubMed ID: 25869964
[TBL] [Abstract][Full Text] [Related]
16. Poly(ethylene glycol)-poly(ester-carbonate) block copolymers carrying PEG-peptidyl-doxorubicin pendant side chains: synthesis and evaluation as anticancer conjugates.
Andersson L; Davies J; Duncan R; Ferruti P; Ford J; Kneller S; Mendichi R; Pasut G; Schiavon O; Summerford C; Tirk A; Veronese FM; Vincenzi V; Wu G
Biomacromolecules; 2005; 6(2):914-26. PubMed ID: 15762660
[TBL] [Abstract][Full Text] [Related]
17. Improved anticancer efficacy of doxorubicin mediated by human-derived cell-penetrating peptide dNP2.
Xiang Y; Shan W; Huang Y
Int J Pharm; 2018 Nov; 551(1-2):14-22. PubMed ID: 30205127
[TBL] [Abstract][Full Text] [Related]
18. Polymeric nanomedicine for tumor-targeted combination therapy to elicit synergistic genotoxicity against prostate cancer.
Yang Q; Yang Y; Li L; Sun W; Zhu X; Huang Y
ACS Appl Mater Interfaces; 2015 Apr; 7(12):6661-73. PubMed ID: 25775367
[TBL] [Abstract][Full Text] [Related]
19. The structure of polymer carriers controls the efficacy of the experimental combination treatment of tumors with HPMA copolymer conjugates carrying doxorubicin and docetaxel.
Šírová M; Strohalm J; Chytil P; Lidický O; Tomala J; Říhová B; Etrych T
J Control Release; 2017 Jan; 246():1-11. PubMed ID: 27940304
[TBL] [Abstract][Full Text] [Related]
20. Synergistic enhancement of anticancer therapeutic efficacy of HPMA copolymer doxorubicin conjugates via combination of ligand modification and stimuli-response srategies.
Li L; Zhou M; Huang Y
Int J Pharm; 2018 Jan; 536(1):450-458. PubMed ID: 29237570
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
